01:58 PM EST, 11/20/2025 (MT Newswires) -- Medexus Pharmaceuticals ( MEDXF ) on Thursday said it received exchange approvals to launch a normal course issuer bid (NCIB)..

The company may buy back for cancellation up to 2.98-million shares, about 10% of the public float. As of Nov. 12, the company had 32.4-million shares outstanding and a public float of 29.8-million shares.

Purchases under the NCIB may start on Nov. 24, and continue through Nov. 23, 2026, or such earlier date as the company completes the maximum purchases permitted. The NCIB will be funded using its general funds.

Shares of the company were last seen down $0.09 $2.56 on the Toronto Stock Exchange.

Price: 2.56, Change: -0.09, Percent Change: -3.40